Pierre Legault - 20 Dec 2021 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role
Director
Signature
/s/ Michael A. Metzger, as Attorney-in-Fact
Issuer symbol
SNDX
Transactions as of
20 Dec 2021
Transactions value $
-$617,736
Form type
4
Filing time
22 Dec 2021, 17:25:16 UTC
Next filing
05 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SNDX Common Stock Options Exercise $141,600 +20,000 +125% $7.08 36,000 20 Dec 2021 Direct
transaction SNDX Common Stock Sale -$420,250 -20,000 -55.6% $21.01 16,000 20 Dec 2021 Direct F1, F2
transaction SNDX Common Stock Options Exercise $189,120 +24,000 +150% $7.88 40,000 22 Dec 2021 Direct
transaction SNDX Common Stock Sale -$528,206 -24,000 -60% $22.01 16,000 22 Dec 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -20,000 -100% $0.000000* 0 20 Dec 2021 Common Stock 20,000 $7.08 Direct F4
transaction SNDX Stock Options (Right to buy) Options Exercise $0 -24,000 -100% $0.000000* 0 22 Dec 2021 Common Stock 24,000 $7.88 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 63,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested.
F2 The sale prices ranged from $21.00 to $21.0238.
F3 The sale prices ranged from $22.00 to $22.02.
F4 This option is fully vested.